<DOC>
	<DOCNO>NCT00293397</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , doxorubicin , work different way stop growth tumor cell , either kill cell stop dividing . Chemoembolization kill tumor cell block blood flow tumor keep chemotherapy drug near tumor . PURPOSE : This clinical trial study well chemoembolization use doxorubicin work treat patient liver cancer remove surgery .</brief_summary>
	<brief_title>Chemoembolization Using Doxorubicin Treating Patients With Liver Cancer That Can Be Removed By Surgery</brief_title>
	<detailed_description>OBJECTIVES : - Determine , preliminarily , feasibility chemoembolization GelSpheres™ bead mixed doxorubicin hydrochloride patient unresectable hepatocellular carcinoma . OUTLINE : This pilot study . Patients undergo catheterization hepatic artery follow chemoembolization comprise infusion GelSpheres™ bead mixed doxorubicin hydrochloride target hepatic artery . Patients may receive 3 chemoembolization treatment . After completion study treatment , patient follow 1 month , every 2 month 1 year , every 3 month year 2 . PROJECTED ACCRUAL : A total 20 patient accrue study .</detailed_description>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis hepatocellular carcinoma ( HCC ) accord European Association Study Liver ( EASL ) disease diagnostic criterion AND Okuda stag classification No advance disease , define follow : Barcelona Clinic Liver Cancer ( BCLC ) class C disease , define follow : Vascular invasion , include segmental portal obstruction Extrahepatic spread Cancerrelated symptom ( PST 12 ) BCLC class D disease , define follow : Okuda stage III disease WHO performance status 3 4 Diffuse HCC , define massive illdefined tumor involvement ChildPugh Class C Not eligible radical therapy ( e.g. , resection , liver transplantation , percutaneous therapy ) No significant liver decompensation Preserved liver function ( ChildPugh class AB ) No ascites ( trace ascites allow ) No active primary tumor Arteries supply lesion must large enough accept GelSpheres™ bead PATIENT CHARACTERISTICS : Bilirubin ≤ 3 mg/dL Albumin &gt; 2.0 g/dL AST ALT ≤ 5 time upper limit normal ( ULN ) Alkaline phosphatase ≤ 5 time upper limit normal ( ULN ) No active gastrointestinal bleeding No encephalopathy No contraindication hepatic embolization procedure , indicate following : Portosystemic shunt Hepatofugal blood flow Platelet count &lt; 50,000/mm^3 INR ≥ 1.8 PTT ≥ 39 second Renal failure Severe atheromatosis No contraindication doxorubicin hydrochloride administration , indicate following : Bilirubin &gt; 5 mg/dL WBC &lt; 1,500/mm^3 Ejection fraction &lt; 50 % isotopic ventriculography echocardiography Not pregnant No known allergy contrast medium No intolerance occlusion procedures No vascular anatomy bleed would preclude catheter placement embolus injection , indicate following : Active risk hemorrhage Patent extratointracranial anastomosis shunt End artery lead directly cranial nerve Feeding artery small distal branch emerge Collateral vessel pathway would potentially endanger normal territory embolization PRIOR CONCURRENT THERAPY : No prior anticancer therapy HCC</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>adult primary hepatocellular carcinoma</keyword>
	<keyword>localize unresectable adult primary liver cancer</keyword>
</DOC>